Zobrazeno 1 - 10
of 570
pro vyhledávání: '"Guru Sonpavde"'
Autor:
Harish Seethapathy, Sarah Street, Xiao Wei, Shveta S. Motwani, Kerry L. Reynolds, Toni K. Choueiri, Nifasha Rusibamayila, Ian A. Strohbehn, Meghan Lee, M.D. Michaelson, Brad McGregor, Cristina Salabao, Guru Sonpavde, Meghan E. Sise, David E. Leaf, Shruti Gupta, Sophia H. Zhao, Donald F. Chute, Xin Gao, Marina D. Kaymakcalan, Osama E. Rahma
Publikováno v:
European Journal of Cancer. 157:50-58
Background In patients with genitourinary cancers, the effect of immune checkpoint inhibitors (ICIs) on kidney function is unknown. Patients and methods This is a retrospective cohort study of patients with renal cell carcinoma (RCC) and urothelial c
Autor:
Syed A. Hussain, Catherine Curran, Giuseppe Di Lorenzo, Ruby Gupta, Pasquale Verolino, Moshe Chaim Ornstein, Petros Grivas, Archana Agarwal, Mehmet Asim Bilen, Jorge A. Garcia, Guru Sonpavde, Alexandra Drakaki, Pedro C. Barata, Gregory R. Pond, Jae-Lyun Lee, Ravindran Kanesvaran
Publikováno v:
Clinical Genitourinary Cancer. 19:425-433
PD1/L1 inhibitors are approved by FDA as first-line therapy for patients with advanced urothelial carcinoma (aUC) who are cisplatin-ineligible with high tumor PD-L1 expression or are platinum-ineligible regardless of PD-L1 expression. However, the ou
Autor:
Jonathan L. Wright, Alexander Sankin, Petros Grivas, Ignacio Duran, Ali Raza Khaki, Dimitrios Makrakis, Pedro C. Barata, Guru Sonpavde, Benjamin A. Gartrell, Vadim S. Koshkin, Evan Shreck, Lucia Carril-Ajuria, David J. Pinato, Mehmet Asim Bilen, Neeraj Agarwal, Mark P. Lythgoe, Giuseppe Di Lorenzo, Jayanshu Jain, Daniel Castellano, Ivan de Kouchkovsky, Rana R. McKay, Jure Murgic, Tyler F. Stewart, Michael Edward Devitt, Rafee Talukder, Pedro Isaacsson-Velho, Sandy T. Liu, Rafael Morales-Barrera, Lucia Alonso Buznego, Marcus Marie Moses, Leonidas Nikolaos Diamantopoulos, Aristotelis Bamias, Joseph J. Park, Ana Fröbe, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Victor Sacristan Santos, Monika Joshi, Evan Y. Yu, Alejo Rodriguez-Vida, Michael Grant, Ajjai Alva, Christopher J. Hoimes, Abhishek Tripathi
Publikováno v:
BJU international, vol 130, iss 5
BJU Int
BJU Int
OBJECTIVES: To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64617a8b9d10e6092cd0be747466efd
https://escholarship.org/uc/item/8678m8j9
https://escholarship.org/uc/item/8678m8j9
Autor:
Sarah Abou Alaiwi, Amin Nassar, Guru Sonpavde, Elio Adib, Tarek H. Mouhieddine, Toni K. Choueiri, Marios Giannakis, Elie W. Akl, David J. Kwiatkowski, Kent W. Mouw, F. Stephen Hodi, Robert I. Haddad, Alexander Gusev, Pier Vitale Nuzzo, Sachet A. Shukla, David A. Braun
Publikováno v:
Clin Cancer Res
Purpose: Immune checkpoint inhibitors (ICI) have shown clinical benefit in many types of metastatic cancers with only a few predictive biomarkers identified so far. CDKN2A is commonly altered in human cancers, but prior studies have provided conflict
Publikováno v:
Hematol Oncol Clin North Am
At diagnosis, more than 70% of bladder cancers (BCs) are at the non-muscle-invasive bladder cancer (NMIBC) stages, which are usually treated with transurethral resection followed by intravesical instillation. For the remaining advanced cancers, syste
Autor:
Devika Das, Terry Hyslop, Steven R. Patierno, Guru Sonpavde, Bonnie LaCroix, Tian Zhang, Brendon M. Patierno, Julia Rasmussen, Andrew J. Armstrong, A. Oliver Sartor, Patrick Healy, Kouros Owzar, James D. Bearden, Jennifer A. Freedman, Michael Moses Goodman, Kellie Shobe, Matthew I. Milowsky, Mark D. Fleming, Megan Ann McNamara, Michael R. Harrison, Julie Kephart, William R. Berry, Rhonda Wilder, Monika Anand, Carol Winters, Rick A. Kittles, Rhonda L. Bitting, Dadong Zhang, Colleen Riggan, Daniel J. George, Alexander B. Sibley, Elisabeth I. Heath, Susan Halabi
Publikováno v:
Cancer
BACKGROUND: Retrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus pre
Autor:
Aristotelis Bamias, Vadim S. Koshkin, Victor Sacristan Santos, Matthew D. Galsky, Ana Fröbe, Joseph J. Park, David J. Pinato, Pedro Isaacsson Velho, Christopher J. Hoimes, Pavlos Msaouel, Jayanshu Jain, Daniel Castellano, Leonidas Nikolaos Diamantopoulos, Benjamin A. Gartrell, Neeraj Agarwal, Abhishek Tripathi, Ali Raza Khaki, Rafael Morales-Barrera, Ajjai Alva, Stepan M. Esagian, Lucia Carril-Ajuria, Jure Murgic, Tyler F. Stewart, Sandy T. Liu, Evan Shreck, Monika Joshi, Noah M. Hahn, Pedro C. Barata, Mehmet Asim Bilen, Lucia Alonso Buznego, Marcus Marie Moses, Ivan de Kouchkovsky, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Petros Grivas, Evan Y. Yu, Alejo Rodriguez-Vida, Ignacio Duran, Alexander Sankin, Mark P. Lythgoe, Guru Sonpavde, Rana R. McKay, Michael Edward Devitt
Publikováno v:
BJU International. 128:196-205
Objectives: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients and methods: We perfo
Autor:
Lorine Häuser, Karl H. Tully, Quoc-Dien Trinh, Matthew Mossanen, Guru Sonpavde, Adam S. Kibel, Florian Roghmann, Joachim Noldus, Xi Chen
Publikováno v:
Clinical Genitourinary Cancer. 18:e651-e659
The objective of this study was to examine the overall survival (OS) in patients diagnosed with high-grade T1 non-muscle-invasive bladder cancer treated with early radical cystectomy versus local treatment of the primary tumor, defined as endoscopic
Publikováno v:
Archives of Pathology & Laboratory Medicine. 145:1000-1008
Context.— Plasmacytoid urothelial carcinoma (PC-UC) is an aggressive variant of urothelial carcinoma (UC), characterized by loss of E-cadherin (E-Cad)–mediated intercellular adhesion. Loss of E-Cad by immunohistochemistry can help diagnose PC-UC;
Autor:
Amishi Yogesh Shah, Arlene O. Siefker-Radtke, Aradhana M. Venkatesan, Subrina Farah, Glenn J. Bubley, Mehmet Asim Bilen, Wanling Xie, Matthew T. Campbell, Guru Sonpavde, Kerry L. Kilbridge, Amir Mortazavi, Atish D. Choudhury, Toni K. Choueiri, Bradley Alexander McGregor, Andrew Schmidt, Rana R. McKay
Publikováno v:
Cancer. 127:840-849
Background In this multicenter, single-arm, multicohort, phase 2 trial, the efficacy of nivolumab and ipilimumab was evaluated in patients with advanced rare genitourinary cancers, including bladder and upper tract carcinoma of variant histology (BUT